|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
News Releases, information, etc. from the "Exelon" corporate website are green | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Saturday
Exelon (Rivastigmine Tartrate) Now Available In US For Alzheimer's Disease:
Novartis Pharmaceuticals Corporation announced today that Exelon® (rivastigmine tartrate) capsules -- the first new Alzheimer's disease medication in three years -- is now on pharmacy shelves and available by prescription. Exelon is a cholinesterase inhibitor for the treatment of mild to moderate Alzheimer's disease (AD). The safety and efficacy of Exelon were demonstrated in the largest phase III clinical program to date of any Alzheimer's disease medication. Patients treated with Exelon demonstrated a significant benefit in global functioning based on evaluation of activities of daily living (ADLs), behavior and cognition. |